Antisense Gene Therapy

New RNA treatment inhibits growth of solid tumors

Published in Gene Therapy Weekly, March 14th, 2002

by Sonia Nichols, senior medical writer - Antisense gene therapy blocks tumor growth and angiogenesis in mice implanted with esophageal squamous cell carcinoma. Similar therapy could be effective for augmenting standard cancer therapies targeting solid tumors, researchers report.

Using current techniques, medical researchers in China at the Fourth Military Medical University have developed gene therapy consisting of antisense RNA to vascular endothelial growth factor (165), one of the growth factor's major isoforms. Initial results indicate it may be a prospective candidate for treating solid tumors that progress largely as a result of angiogenesis.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-03-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry